PROJECTS
>>Ramp up of Product Development Efficiencies
>>Transformation through In-Licensing & Site Transfers
>>Out-License of New Molecular Entity by Biotech Footprint Late
>>Strengthening of Overseas Footprint
>>Divestment of Late Life Cycle Products
>>Commercializing a Reformulated Product
>>Business Development for Development Stage Enabling Technology
>>Restructuring Clinical Operations
>>Optimal Drug Development Path and Licensing Process
>>Post-Merger integration of Research and Development operations
Out-License of New Molecular Entity by Biotech
A US-based pharmaceutical development company had attempted to interest larger pharmaceutical companies in its lead compound, a new molecular entity indicated in a specialty therapeutic area. The company had experienced difficulties in gaining access to decision makers within the targeted companies, and in communicating the benefits of the compound, effectively. Garphi and its associate company were asked to take over the licensing initiative. Garphi with the help of its associate redrafted the non-confidential and confidential documents in order to focus on the anticipated benefits of the compound. Garphi then established contact with several companies who had earlier declined interest, and reintroduced the opportunity. As a result, the small pharmaceutical company signed agreements with 2 mid-sized specialty pharma companies for European and Asian rights.
